Trial Profile
Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 17 Jun 2020
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Interferon alpha-1b; Lopinavir/ritonavir
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- 16 May 2020 New source identified and integrated (Chinese Clinical Trial Register ChiCTR2000029600).
- 24 Mar 2020 New trial record
- 19 Mar 2020 According to an Zhejiang Hisun Pharmaceutical Media Release, preliminary results of this study were released at a press conference held by the Ministry of Science and Technology of the P.R.C.